EyePoint Pharmaceuticals Says Phase 3 Eye Drug Trials Clear Safety Review

MT Newswires Live20:12

EyePoint Pharmaceuticals (EYPT) said Thursday that an independent safety committee recommended that late-stage trials of its experimental drug, Duravyu, for wet age-related macular degeneration continue without changes after completing a scheduled safety review.

The company said interim masked safety data continued to show a favorable safety profile for the drug, consistent with results seen in more than 190 patients across four completed studies.

The trials are comparing Duravyu, administered every six months, with aflibercept in more than 900 patients with the condition to demonstrate that it is not inferior to aflibercept in preserving vision at Weeks 52 and 56, the company added.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2635712469?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-14 20:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2635712469","market":"sg","top_or_hot":-1,"title":"EyePoint Pharmaceuticals Says Phase 3 Eye Drug Trials Clear Safety Review","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/EYPT\">EyePoint</a> Pharmaceuticals (EYPT) said Thursday that an independent safety committee recommended that late-stage trials of its experimental drug, Duravyu, for wet age-related macular degeneration continue without changes after completing a scheduled safety review.</p><p>The company said interim masked safety data continued to show a favorable safety profile for the drug, consistent with results seen in more than 190 patients across four completed studies.</p><p>The trials are comparing Duravyu, administered every six months, with aflibercept in more than 900 patients with the condition to demonstrate that it is not inferior to aflibercept in preserving vision at Weeks 52 and 56, the company added.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EyePoint Pharmaceuticals Says Phase 3 Eye Drug Trials Clear Safety Review</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEyePoint Pharmaceuticals Says Phase 3 Eye Drug Trials Clear Safety Review\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-05-14 20:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/EYPT\">EyePoint</a> Pharmaceuticals (EYPT) said Thursday that an independent safety committee recommended that late-stage trials of its experimental drug, Duravyu, for wet age-related macular degeneration continue without changes after completing a scheduled safety review.</p><p>The company said interim masked safety data continued to show a favorable safety profile for the drug, consistent with results seen in more than 190 patients across four completed studies.</p><p>The trials are comparing Duravyu, administered every six months, with aflibercept in more than 900 patients with the condition to demonstrate that it is not inferior to aflibercept in preserving vision at Weeks 52 and 56, the company added.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2635712469","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2635712469","pubTimestamp":1778760773,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"EyePoint Pharmaceuticals  said Thursday that an independent safety committee recommended that late-stage trials of its experimental drug, Duravyu, for wet age-related macular degeneration continue without changes after completing a scheduled safety review.The company said interim masked safety data continued to show a favorable safety profile for the drug, consistent with results seen in more than 190 patients across four completed studies.The trials are comparing Duravyu, administered every six months, with aflibercept in more than 900 patients with the condition to demonstrate that it is not inferior to aflibercept in preserving vision at Weeks 52 and 56, the company added.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4588":"碎股","EYPT":"EyePoint","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4007":"制药","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)"},"translate_title":"EyePoint Pharmaceuticals表示3期眼科药物试验通过安全审查","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EYPT":1.5},"content_text":"EyePoint Pharmaceuticals (EYPT) said Thursday that an independent safety committee recommended that late-stage trials of its experimental drug, Duravyu, for wet age-related macular degeneration continue without changes after completing a scheduled safety review.The company said interim masked safety data continued to show a favorable safety profile for the drug, consistent with results seen in more than 190 patients across four completed studies.The trials are comparing Duravyu, administered every six months, with aflibercept in more than 900 patients with the condition to demonstrate that it is not inferior to aflibercept in preserving vision at Weeks 52 and 56, the company added.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2635712469","isCrawlerRequest":true}